Ebola Vaccine Trial (Ad26.ZEBOV/MVA-BN-Filo)

2019-07-25 11:52:33 | BioPortfolio


An open-label, single arm phase II study of the candidate Ebola Vaccine Ad26.ZEBOV/MVA-BN®-Filo


This is an interventional, single arm, open-label, non-randomized, phase II study to accumulate additional data on immunogenicity and safety of Ad26.ZEBOV/MVA-BN®-Filo against Ebola virus disease.

It also has a qualitative component to better understand knowledge about Ebola virus disease and the perception and attitudes towards the vaccine amongst participants (Healthcare and Frontline workers).

Study Design


Ebola Virus Disease




MRC/UVRI & LSHTM Uganda Research Unit


Not yet recruiting


MRC/UVRI Uganda Research Unit on Aids

Results (where available)

View Results


Published on BioPortfolio: 2019-07-25T11:52:33-0400

Clinical Trials [860 Associated Clinical Trials listed on BioPortfolio]

A Study to Evaluate A Range of Dose Levels of Ad26.ZEBOV and MVA‐BN‐Filo in Healthy Adult Participants

The purpose of this study is to demonstrate the non‐inferiority of a heterologous prime‐boost regimen using Ad26.ZEBOV as prime and MVA‐BN‐Filo as boost administered at different d...

A Study to Evaluate the Immunogenicity, Safety and Tolerability of Ad26.ZEBOV and MVA‐BN‐Filo in Healthy Adult Participants

The purpose of this study is to demonstrate that 3 different batches of Ad26.ZEBOV as prime and a single batch of MVA‐BN‐Filo as boost at a 56 day interval induce an equivalent humoral ...

Partnership for Research on Ebola VACcinations

The purpose of this study is to evaluate the safety and immunogenicity of three vaccine strategies that may prevent Ebola virus disease (EVD) events in children and adults. Participants wi...

A Study of 2-dose Vaccine Regimen Using 3 Consecutive Lots of Ad26.ZEBOV and MVA-BN-Filo in Adult Participants

The purpose of this study is to demonstrate that the paired 2-dose vaccine regimens from 3 consecutively manufactured lots of Adenovirus serotype 26 encoding the Ebola virus Mayinga glycop...

Safety, Tolerability and Immunogenicity Study of 2 Prime-boost Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo

The purpose of this study is to assess the safety, tolerability and immunogenicity of different vaccination schedules of Ad26.ZEBOV and MVA-BN-Filo administered intramuscularly (IM) as het...

PubMed Articles [17888 Associated PubMed Articles listed on BioPortfolio]

Post-exposure prophylaxis with rVSV-ZEBOV following exposure to a patient with Ebola virus disease relapse in the UK: an operational, safety and immunogenicity report.

In October 2015, 65 people came into direct contact with a healthcare worker presenting with a late reactivation of Ebola virus disease (EVD) in the UK. Vaccination was offered to 45 individuals with ...

Serum-free production of rVSV-ZEBOV in Vero cells: microcarrier bioreactor versus scale-X™ hydro fixed-bed.

Ebola virus disease outbreaks have repeatedly occurred on the African continent over the last decades, with more serious outbreaks in recent years. Being highly transmissible and associated to high fa...

Pregnancy Outcomes among Women Receiving rVSVΔ-ZEBOV-GP Ebola Vaccine during the Sierra Leone Trial to Introduce a Vaccine against Ebola.

Little information exists regarding Ebola vaccine rVSVΔG-ZEBOV-GP and pregnancy. The Sierra Leone Trial to Introduce a Vaccine Against Ebola (STRIVE) randomized participants without blinding to immed...

Immunogenicity, Lot Consistency, and Extended Safety of rVSVΔG-ZEBOV-GP Vaccine: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study in Healthy Adults.

This double-blind study assessed immunogenicity, lot consistency, and safety of recombinant vesicular stomatitis virus-Zaire Ebola virus envelope glycoprotein vaccine (rVSVΔG-ZEBOV-GP).

Ending Ebola.

Promising vaccines and results from recent clinical trials of therapeutic antibodies against Ebola virus offer hope for an end to this devastating disease. We asked three investigators in the field to...

Medical and Biotech [MESH] Definitions

An Ig domain-containing membrane receptor for HEPATITIS A VIRUS; EBOLA VIRUS; MARBURG VIRUS; and DENGUE VIRUS. It may also function to modulate ASTHMA and HYPERSENSITIVITY.

A highly fatal, acute hemorrhagic fever, clinically very similar to MARBURG VIRUS DISEASE, caused by EBOLAVIRUS, first occurring in the Sudan and adjacent northwestern (what was then) Zaire.

Vaccines or candidate vaccines used to prevent EBOLA HEMORRHAGIC FEVER.

A genus of FLAVIVIRIDAE, also known as mucosal disease virus group, which is not arthropod-borne. Transmission is by direct and indirect contact, and by transplacental and congenital transmission. Species include BORDER DISEASE VIRUS, bovine viral diarrhea virus (DIARRHEA VIRUS, BOVINE VIRAL), and CLASSICAL SWINE FEVER VIRUS.

A genus in the family FILOVIRIDAE consisting of several distinct species of Ebolavirus, each containing separate strains. These viruses cause outbreaks of a contagious, hemorrhagic disease (HEMORRHAGIC FEVER, EBOLA) in humans, usually with high mortality.

More From BioPortfolio on "Ebola Vaccine Trial (Ad26.ZEBOV/MVA-BN-Filo)"

Quick Search

Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Tropical Medicine
Tropical Medicine is the study of diseases more commonly found in tropical regions than elsewhere. Examples of these diseases are malaria, yellow fever, Chagas disease, Dengue, Helminths, African trypanosomiasis, Leishmaniasis, Leprosy, Lymphatic filaria...

Searches Linking to this Trial